工程化 T 细胞记忆以实现抗肿瘤免疫。

Engineering T cell memory for antitumor immunity.

机构信息

Albert Einstein College of Medicine, Bronx, NY, USA.

Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

出版信息

Trends Pharmacol Sci. 2022 Jan;43(1):1-3. doi: 10.1016/j.tips.2021.11.003. Epub 2021 Nov 13.

DOI:10.1016/j.tips.2021.11.003

PMID:34785086

Abstract

Cancer therapy with the T cell growth factor interleukin (IL)-2 is limited by low response rates and toxicity. Multiple protein engineering strategies have attempted to improve IL-2 therapy, typically through enhanced IL-2 receptor (IL-2R) binding. Intriguingly, Mo et al. show that an IL-2R partial agonist may dramatically improve IL-2 responses by altering T cell differentiation.

摘要

癌症治疗中使用 T 细胞生长因子白细胞介素（IL）-2会受到低反应率和毒性的限制。多种蛋白质工程策略试图改善 IL-2 治疗，通常是通过增强 IL-2 受体（IL-2R）结合。有趣的是，Mo 等人表明，通过改变 T 细胞分化，IL-2R 部分激动剂可能会显著改善 IL-2 的反应。